Sort   by:  
 Page size 
ProteomicsA Biomarker Panel for Chronic Graft-versus-Host Disease
Using a quantitative proteomics approach, we compared pooled plasma samples from 35 patients with cGVHD obtained at a median of 103 days post-HCT and 18 patients without cGVHD obtained at matched timepoints to identify biomarkers for cGVHD.
ORGANISM(S): Homo sapiens (Human) 
2016-05-27 | PXD002762 | Pride
Cgvhd Biomarker 
TranscriptomicscGvHD vs. non-cGvHD gene expression profiling in peripheral blood
We performed peripheral blood gene expression profiling to identify an array of transcriptional biomarkers that discriminate presence of active cGvHD requiring immunosuppression following allogeneic HCT. Peripheral blood mononuclear cells were prepared by Ficoll gradient and cryopreserved from 63 pa...
ORGANISM(S): Homo sapiens 
2013-07-11 | E-GEOD-23924 | biostudies-arrayexpress
TranscriptomicscGvHD vs. non-cGvHD gene expression profiling in peripheral blood
We performed peripheral blood gene expression profiling to identify an array of transcriptional biomarkers that discriminate presence of active cGvHD requiring immunosuppression following allogeneic HCT. Peripheral blood mononuclear cells were prepared by Ficoll gradient and cryopreserved from 63 pa...
ORGANISM(S): Homo sapiens 
2013-07-11 | GSE23924 | GEO
GenomicsHomo sapiens
cGvHD vs. non-cGvHD gene expression profiling in peripheral blood
PRJNA130511 | ENA
TranscriptomicsSomatic Gain-of-Function mTOR mutation in Clonally Expanded T-lymphocytes Associated with Chronic Graft-Versus-Host Disease
Graft-versus-host-disease (GvHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HSCT). Here we report studies of a patient with chronic GVHD (cGVHD) carrying persistent CD4+ T cell clonal expansion which harbored somatic mTOR, NFKB2, and TLR2 mutations. Functional an...
ORGANISM(S): Homo sapiens 
2020-04-12 | E-MTAB-8911 | biostudies-arrayexpress
TranscriptomicsDifferential gene expression profile correlates with bortezomib responsiveness in steroid-resistant cGVHD
Nineteen patients with steroid-refractory cGVHD (chronic graft versus host disease) received weekly bortezomib from 2 – 12 months (1.6 mg/m2 q wk x 4 followed by one week of rest). Treatment was well tolerated with no > grade 3 adverse events. Six patients achieved CR or good PR (gPR). Average Rodna...
ORGANISM(S): Homo sapiens 
2017-01-18 | GSE56495 | GEO
UnknownIxazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.
Not available
S-EPMC12848369 | biostudies-literature
UnknownTemporal changes in corticosteroid dose during ibrutinib treatment in patients with cGVHD and pulmonary involvement.
Not available
S-EPMC11861523 | biostudies-literature
TranscriptomicsIL13 and CCL2 Drive Disease in an Inflammatory Subset of Scleroderma
This SuperSeries is composed of the following subset Series: GSE17914: IL13 and CCL2 Drive Disease in an Inflammatory Subset of Scleroderma [cGVHD] GSE24403: IL13 and CCL2 drive disease in an inflammatory subset of Scleroderma [IL13] GSE24409: IL13 and CCL2 drive disease in an inflammatory subset of...
ORGANISM(S): Homo sapiens 
2011-06-30 | E-GEOD-24410 | biostudies-arrayexpress
UnknownImpaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD.
Not available
S-EPMC6156893 | biostudies-literature
Sort   by:  
 Page size